GDF-8 (Myostatin)
Aliases: Myostatin · Growth differentiation factor 8
Last verified: 2026-09-24
The short version
GDF-8 on a vendor's list is a categorical error marketed as a product: myostatin is an inhibitor of muscle growth, so 'adding myostatin' is biologically opposite to every fitness goal. The likely explanation: someone realized the gray market sells anything with a 'peptide' label, or GDF-8 got mixed up with the 'myostatin inhibitor' narrative (follistatin, ACE-031 — which have their own development disasters). If anything illustrates that gray-market sales have no pharmacological editor, it is a vial of a hormone whose only known effect is smaller muscles.
Identity & type
- Molecular type
- protein ligand
- Molecular weight
- ~26 kDa (dimer)
- Origin
- Recombinant human myostatin — soluble growth differentiation factor 8.
Mechanism of action
GDF-8 is myostatin — an endogenous TGF-beta-family ligand that is a negative regulator of muscle growth: it binds activin receptor IIB → Smad2/3 signaling → inhibition of myogenesis. 'Buying GDF-8' is buying the muscle-growth inhibitor itself, not its blocker.
not confirmed in humans
Dosing & routes
Official / clinical context
No official context for use exists; the fundamental literature describes its role.
Regulator-approved labeling and published study designs — never a recommendation.
Community-reported practice
No legitimate community practice; occasional appearance in 'research' categories without a single reported regimen or result.
Unverified self-reports. Not medical advice. Not endorsement.
Protocol — official vs community
Official / label
No protocol applies — GDF-8 is myostatin itself, the endogenous negative regulator of muscle growth. The therapeutic direction is inhibiting it, not administering it; 'buying GDF-8' is buying the brake, not the accelerator.
Duration: —
Every drug in this space — myostatin antibodies, follistatin, ACE-031-type ActRIIB traps — targets this ligand. See those entries for actual protocols.
Community (anecdotal)
Not applicable as a substance. Community 'myostatin inhibition' practice routes through follistatin-344, follistatin-related peptides, or ACE-031-type products.
- Cycle:
- Follows the inhibitor used (typically short 10–30 day courses for follistatin-type products).
- Break:
- Follows the inhibitor used.
This entry exists to orient: the protocol question in the myostatin space is always about the inhibitor, its dose, and its off-target effects (activin blockade, reproductive consequences) — never about GDF-8 itself.
Human evidence
For GDF-8 as a therapeutic substance — it makes no sense to look; genetic evidence of myostatin's role in humans exists, but it speaks about inhibitors, not about adding the ligand.
Preclinical evidence
One of the most influential animal studies ever (Nature 1997) — as the basis for the opposite strategy.
Known risks
- Opposite of the desired outcome (loss of muscle mass) if the product really is what it claimstheoretical
- Unknown content of the gray vialcharacterized
Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.
Unknowns & evidence gaps
- Why this is sold at all — that is the only real unknown
Frequently asked questions
References
- McPherron AC, Lawler AM, Lee SJ. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature, 1997
- Myostatin inhibitor clinical programs (bimagrumab, apitegromab) — strategy is inhibition, not administration